Revolutionary Saliva Test Validated for Endometriosis – Femtech Insider
Femtech Insider shared a post on LinkedIn:
“NEJM Evidence has published a validation study for Ziwig Biotech Endotest, a saliva-based diagnostic test for endometriosis. The study reports results from a prospective, independent, multicenter clinical trial conducted across 17 public and private hospitals in France.
The study reported sensitivity of 97.3%, specificity of 94.1%, overall accuracy of 96.6%, positive predictive value of 98.2%, and negative predictive value of 91.3%. Performance remained consistent across all subgroups, regardless of hormonal treatment, analgesic use, inclusion site, or sequencing conditions.
‘This publication in NEJM Evidence is a major step forward for science and for women affected by endometriosis. We are deeply grateful to all the women, hospitals, and healthcare professionals whose commitment and support have been essential in bringing this innovation to patients.’ Yahya EL MIR, Founder and President at Ziwig Biotech.
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Jan 28, 2026, 16:59Unlocking the Potential of Menstrual Blood in Health Testing – Global Women’s Health Innovation Conclave
-
Jan 28, 2026, 16:57New Insights on Oocyte Yield in Endometriosis and PCOM – RBMO
-
Jan 28, 2026, 16:51Transform Your Expertise with ESHRE eCampus Learning – ESHRE
-
Jan 28, 2026, 16:46Accelerate Your Growth at the AP3G National Meeting – ASRM
-
Jan 28, 2026, 16:43Debojit Saha: Unraveling Chromosomal Errors in Aging Human Eggs
-
Jan 28, 2026, 16:38Silvia Vannuccini: RBMO Highlights Key Insights on Adenomyosis Awareness
-
Jan 28, 2026, 16:32Maximilian Attwood: Challenging Medical Misogyny in Endometriosis Research
-
Jan 28, 2026, 16:29Ioakeim Sapantzoglou: New Perspectives on Fetal Growth Restriction and Genetic Testing
-
Jan 28, 2026, 16:26Enhancing Pre-Eclampsia Prediction with Doppler Indices – ISUOG